No Carolina / NY / Florida
Ph: 561.316.3330

spot_img

Gyros Protein Technologies Introduces Gyrolab Generic Rodent ADA Kit Reagents to Support Preclinical Immunogenicity Assessment

The new Roden ADA Kit expedites bioanalysis by removing the need for assay development and optimization across molecules to provide robust, reproducible, reliable data from nanoliter sample volumes. This is beneficial when ADA assessment is evaluated in preclinical animal models where sample volume may be limited.

Combining AI Models Improves Breast Cancer Risk Assessment

Summation

  • Using AI to identify a women's breast cancer risk from a single mammogram will not only result in earlier cancer detection but can also improve the strain on the health care system due to the worldwide shortage of specialized breast radiologists.
  • The combined AI model was tested on a study group of more than 119,000 women who were included in a breast cancer screening program in the Capital Region of Denmark between November 2012 and December 2015.
  • Combining AI systems for short- and long-term breast cancer risk results in an improved cancer risk assessment, according to a study published in Radiology.

Combining AI systems for short- and long-term breast cancer risk results in an improved cancer risk assessment, according to a study published in Radiology.

Using mammography-based deep learning models may improve the accuracy of breast cancer risk assessment and can also lead to earlier diagnoses.

“About 1 in 10 women develop breast cancer throughout their lifetime,” said study author Andreas D. Lauritzen, PhD, from the Department of Computer Science at the University of Copenhagen in Denmark. “In recent years, AI has been studied for the purpose of diagnosing breast cancer earlier by automatically detecting breast cancers in mammograms and measuring the risk of future breast cancer.”

Diagnostic AI models are trained to detect suspicious lesions on mammograms and are well suited to estimate short-term breast cancer risk.

More suitable for long-term breast cancer risk are texture AI models, capable of identifying breast density. Women with dense breast tissue are at higher risk of developing breast cancer and may benefit from supplemental MRI screening.

“It is important to enable reliable and robust assessment of breast cancer risk using information from the screening mammogram,” Dr. Lauritzen said.

Full-field digital mammograms (right mediolateral oblique view) in a 59-year-old woman show (A) the screening mammogram obtained during the study period and (B) the screening mammogram obtained in the subsequent screening round. The first screening mammogram (A) had a very low combined risk score (lowest 0.1%) as determined by the combination model with texture risk and the examination score. The woman was not recalled and did not receive a breast cancer diagnosis throughout the 5-year follow-up.

Risk Assessment Better for Interval and Long-Term Cancer Detection

For this study, Dr. Lauritzen and his research team sought to identify whether a commercially available diagnostic AI tool and an AI texture model, trained separately and then subsequently combined, may improve breast cancer risk assessment.

The researchers used the diagnostic AI tool Transpara and a texture model that was developed by the researchers. A Dutch training set of over 39,000 exams was used to train the models. The short- and long-term risk models were combined using a three-layer neural network.

The combined AI model was tested on a study group of more than 119,000 women who were included in a breast cancer screening program in the Capital Region of Denmark between November 2012 and December 2015. The average age of the women was 59 years.

Compared to the diagnostic and texture models alone, the combined AI model showed an overall improved risk assessment for both interval and long-term cancer detection.

The model also enabled identification of women at high risk for breast cancer. Women identified by the combined model as having the 10% highest combined risk accounted for 44.1% of interval cancers and 33.7% of long-term cancers.

Listen as Dr. Lauritzen, PhD, discusses his research.

Using AI to identify a women’s breast cancer risk from a single mammogram will not only result in earlier cancer detection but can also improve the strain on the health care system due to the worldwide shortage of specialized breast radiologists.

“Current state-of-the-art clinical risk models require multiple tests such as blood work, genetic testing, mammogram and filling out extensive questionnaires, all of which would substantially increase the workload in the screening clinic,” Dr. Lauritzen said. “Using our model, risk can be assessed with the same performance as the clinical risk models but within seconds from screening and without introducing overhead in the clinic.”

SonoVascular Enters Into Strategic Collaboration with Lantheus Holdings | for Use of Microbubbles in Combination with SonoThrombectomy™ System for Treatment of Venous Thromboembolism

"SonoVascular is honored to have the opportunity to partner with Lantheus, a leader in microbubble development," said Daniel Estay, Founder and Chief Executive Officer of SonoVascular. "Our SonoThrombectomy System, combined with Lantheus' microbubbles, is designed to provide a true, next-generation solution for the treatment of DVT and PE that overcomes the drawbacks associated with catheter-based thrombectomy and thrombolysis devices."

Anaut Announces Japanese Regulatory Approval of AI-Powered Surgical Visualization Tool, Eureka α

Eureka α utilizes state-of-the-art AI to analyze real-time video from laparoscopic and robotic surgery, enhancing surgeons' accuracy by highlighting the dissection planes characterized by connective tissue.

Discover Reeva FT: Revolutionizing Wound Covering for Healthcare Pros

Reeva FT is offered in a variety of sizes: 2x2 cm, 2x3 cm, 4x4 cm, 4x6 cm, 4x8 cm, and 10x15 cm. Reeva FT is confirmed by the FDA Tissue Reference Group to meet the criteria for regulation solely under Section 361 of the PHS Act as defined in 21 CFR Part 1271.
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

By using this website you agree to accept Medical Device News Magazine Privacy Policy